Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomea Fusion Inc (NQ: BMEA )

9.040 -0.330 (-3.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biomea Fusion Inc

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Gold Falls Sharply; Geron Shares Spike Higher
Via Benzinga
Why Biomea Fusion (BMEA) Stock Is Down 60%
Biomea Fusion shares are trading lower by 62.7% during Friday's session. The company received notice from the FDA that Its trials of BMF-219 have been placed on clinical hold. 
Via Benzinga
Exposures Product Safety
US Stocks Lower; Nonfarm Payrolls Increase More Than Expected
Via Benzinga
Biomea Fusion Crashes 65% After FDA Puts Diabetes Treatment Studies On Hold
The FDA cited concerns of liver toxicity, but the company says its drug has been generally well-tolerated. 
Via Investor's Business Daily
Exposures Product Safety
Recap: Biomea Fusion Q4 Earnings
Via Benzinga
Why Is Virax Biolabs (VRAX) Stock Down 15% Today?
Virax Biolabs stock is down on Friday as shares of VRAX come off of a massive rally yesterday that didn't come with any news. 
Via InvestorPlace
Vail Resorts Posts Downbeat Q3 Results, Joins Concrete Pumping, DocuSign And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Why Is Biomea Fusion (BMEA) Stock Down 63% Today?
Biomea Fusion stock is falling on Friday after investors learned of the FDA placing a clinical hold on its Phase I/II clinical trials. 
Via InvestorPlace
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking out on Friday as we dig into all of the biggest news affecting shares this morning! 
Via InvestorPlace
This Pharma Stock Dropped 60% Premarket As FDA Halted Diabetes Drug Trials
Elevated liver enzyme levels were noted, although most adverse events were mild to moderate, with no severe reactions reported. 
Via Benzinga
Exposures Product Safety
Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze
Though short squeezes are never guaranteed, these three potential short squeeze stocks could provide generous returns if bought right. 
Via InvestorPlace
Why Braze Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
From Biomea Fusion, Inc.
Via GlobeNewswire
Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations
Sometimes the bears can push their luck too much, leading to a reverse response. That’s the incentive behind these short squeeze stocks. 
Via InvestorPlace
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells 
From Biomea Fusion, Inc.
Via GlobeNewswire
BMEA Stock Earnings: Biomea Fusion Misses EPS for Q1 2024
BMEA stock results show that Biomea Fusion missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
BMEA Stock Earnings: Biomea Fusion Misses EPS for Q4 2023
BMEA stock results show that Biomea Fusion missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
Bullish speculators could have their opportunity to blow up the bears with these short-squeeze stocks to buy. 
Via InvestorPlace
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.